Tripos to Acquire Pharsight for $57M
 
Tripos said this week that it will acquire clinical software and regulatory services firm Pharsight for approximately $57 million in cash.
 
Tripos, owned by private equity firm Vector Capital, will pay $5.50 for each outstanding share of common stock of publicly traded Pharsight. The price represents a 29 percent premium over the average closing price of Pharsight’s stock for the 30-day trading period ended Sept. 8, the day before the acquisition was announced.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.